For patients with nephrolithiasis, sodium-glucose cotransporter-2 (SGLT-2) inhibitor use is associated with a reducti ...

The following is a summary of “Sodium-glucose cotransporter 2 inhibitors and glaucoma in patients with type 2 diabetes,” ...

NEW research has revealed that sodium-glucose cotransporter 2 inhibitors (SGLT2is) are associated with an 18% reduction in ...

Semaglutide, the weight management drug sold as Ozempic and Wegovy, may reduce the risk of Alzheimer's disease by 40% to 70% compared to similar medications, a new study found. But experts say more ...

"In the emulated clinical trial, the use of SGLT2 inhibitors compared to DPP4 inhibits was linked to significantly lower ...

Total Revenue of $93.4 Million for the Third Quarter of 2024, Reflecting 18% Growth Over the Third Quarter of 2023- -NDA Submission for Brensocatib in Bronchiectasis Remains on Track for the Fourth ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

Semaglutide, the active ingredient in Ozempic and Wegovy, may also help lower the risk of developing Alzheimer’s disease in people living with type 2 diabetes.

they identified 16,058 patients with MASLD and type 2 diabetes who initiated a GLP-1 RA between 2006 and 2022 and an equal number of propensity score–matched patients who initiated a dipeptidyl ...

dipeptidyl peptidase 4 inhibitors, sodium-glucose cotransporter 2 inhibitors, sulfonylurea, and thiazolidinedione. Over 3 years, treatment with semaglutide was associated with significantly ...

Share on Pinterest More evidence suggests that semaglutide drugs could help lower the risk of Alzheimer’s disease. Image credit: Scharvik/Getty Images. Past research shows that people with type ...